Update on olaparib in ovarian cancer

Bookmark and Share
Published: 6 Jun 2016
Views: 2534
Prof Jonathan Ledermann - University College Hospital Medical School, London, UK

Prof Ledermann talks to ecancertv at ASCO 2016 about the updated survival data associated with the PARP inhibitor olaparib in a certain subset of ovarian cancer patients.

He also highlights the novel exploratory endpoints that were used for the first time within an oncology trial (TFST and TSST), and highlights that 15% of patients entered into the study possessing mutant strains of BRCA are still receiving maintenance therapy 5 years later.

For future clinical use, it is important to establish precisely those patients who will benefit the most, due to the cost of the drug.